American journal of therapeutics最新文献

{"title":"Off-Label Use of Monoclonal Antibodies in Developing Countries.","authors":"Fatemeh Alizadeh Bengar, Parinaz Sadat Mahmoudi, Hossein Khalili","doi":"10.1097/MJT.0000000000002243","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002243","url":null,"abstract":"<p><strong>Conclusions: </strong>Rituximab was widely used in clinical practice; however, its implementation protocols and safety-monitoring practices varied considerably. In light of these findings, it is important to distinguish between off-label use and inappropriate use, and to ensure that treatment decisions are evaluated against current evidence, clinical guidelines, and indication-specific criteria.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[177Lu]Lu-DOTATATE Versus High-Dose Somatostatin Analogues in Advanced Gastroenteropancreatic Neuroendocrine Tumors: Pooled Evidence From 3 Phase 3 Randomized Trials.","authors":"Muhammad Arsalan, Fnu Sawaira, Taimoor Hassan, Mohammad Omar Khan, Muhammad Mughees, Ahmad Sanan, Muhammad Yasir, Zakir Ullah","doi":"10.1097/MJT.0000000000002247","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002247","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequential Drug Rechallenge Identifying Unusually Concomitant Rifampicin and Pyrazinamide Hepatotoxicity in a Patient Treated for Ganglionar Tuberculosis.","authors":"Nesrine Bensayed, Wafa Baya, Mohamed Ali Khalifa, Ferdaous Chahed, Neila Fathallah, Raoudha Slim, Bouraoui Ouni","doi":"10.1097/MJT.0000000000002212","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002212","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suspected Rosuvastatin-Associated Bullous Pemphigoid: A Diagnostic and Therapeutic Challenge.","authors":"Shirley Gandhi, Barrie Clark, Iman Ashraf, Nadim Qadir, Pramod Reddy","doi":"10.1097/MJT.0000000000002252","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002252","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis of Long-Term Major Adverse Cardiovascular Events of Different Biologics in Psoriatic Patients.","authors":"Zhifeng Liu, Caiyu Liao, Qinyao Zhou, Yufei Wang, Zhiqiang Yin","doi":"10.1097/MJT.0000000000002250","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002250","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic immune-mediated inflammatory disease associated with systemic inflammation and an increased risk of cardiovascular events.</p><p><strong>Areas of uncertainty: </strong>Although biologic therapies have transformed psoriasis treatment, the long-term impact of different biologic classes on major adverse cardiovascular events (MACE) remains unclear.</p><p><strong>Data sources: </strong>A systematic search of PubMed was performed up to May 27, 2026. We included Comparative cohort studies of biologic therapies for psoriasis with follow-up durations of at least 52 weeks, as well as long-term open-label extension phases of randomized controlled trials that reported MACE outcomes. Study quality was assessed using the Newcastle-Ottawa Scale for cohort studies. Hazard ratios (HR) with 95% confidence intervals (CI) were pooled using the generic inverse variance method.</p><p><strong>Results: </strong>Four comparative cohort studies involving 57,331 patients were included in the quantitative synthesis. No significant difference in MACE risk was observed between interleukin (IL)-12/23 inhibitors and tumor necrosis factor alpha (TNF-α) inhibitors (HR: 0.91, 95% CI: 0.68-1.23), or between IL-12/23 inhibitors and IL-17 inhibitors (HR: 1.38, 95% CI: 0.73-2.62). Long-term open-label extension studies reported low MACE event rates (0%-1.33%) across biologic therapies.</p><p><strong>Conclusions: </strong>Among biologic therapies with available long-term comparative data, no significant differences in MACE risk were observed between IL-12/23, TNF-α, and IL-17 inhibitors in patients with psoriasis. Further long-term, large-scale studies are warranted to better define the cardiovascular safety profiles of emerging biologic therapies.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Evolving Landscape of Hypertrophic Cardiomyopathy Treatment: Are Guidelines Keeping Pace?","authors":"Vlad Shusterman, Gidon Salamatbad, Spencer Weintraub, Ronald Wharton","doi":"10.1097/MJT.0000000000002245","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002245","url":null,"abstract":"<p><strong>Background: </strong>Hypertrophic cardiomyopathy (HCM) is a common inherited cardiovascular disorder associated with morbidity. Rapid advances in therapeutics-particularly the emergence of cardiac myosin inhibitors (CMIs)-suggest that current management guidelines are lagging best practices.</p><p><strong>Areas of uncertainty: </strong>Cardiac myosin inhibitors have revolutionized the management of patients with obstructive HCM. Patients with nonobstructive HCM have had limited therapeutic options historically; however, the recently published ACACIA-HCM trial demonstrated significant benefit in these patients and may represent a new treatment option in these patients, although more long-term data and research are needed in this population.</p><p><strong>Data sources: </strong>A literature review was performed using PubMed/MEDLINE, Google Scholar, society guidelines, and recently published clinical trials evaluating HCM, cardiac myosin inhibitors, beta blockers, calcium channel blockers, septal reduction therapy, and emerging therapies for obstructive and nonobstructive HCM.</p><p><strong>Therapeutic advances: </strong>Historically, HCM management has centered on negative inotropic/chronotropic agents to alleviate left ventricular outflow tract obstruction by decreasing the force of contraction and increasing diastolic filling time. The introduction of CMIs represents a paradigm shift by directly targeting the underlying hypercontractility, representing the first therapy specifically designed to treat obstructive HCM, obviating the need for earlier agents, which had limited data and at best modest therapeutic benefit. There may finally be an available treatment for diastolic heart failure in patients with nonobstructive HCM with myosin inhibition, as results from a recent trial ACACIA-HCM were favorable. Furthermore, ongoing investigations are exploring novel approaches such as metabolic modulators.</p><p><strong>Conclusions: </strong>The management of HCM is undergoing substantial transformation, yet guideline recommendations continue to prioritize beta blockers as first-line therapy despite mounting evidence supporting CMIs. Although treatment strategies for obstructive HCM have evolved significantly, optimal approaches for nonobstructive disease remain unclear. Addressing this gap represents a critical priority for future research.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food, Dietary Supplement, and Gut Microbiome Interactions in Oral Anticancer Therapy: Mechanisms, Clinical Consequences, and Management.","authors":"Oana Mîrza, Oana-Monica Leah, Simona Codruța Hegheş, Lorena Filip, Liliana M Rogozea","doi":"10.1097/MJT.0000000000002240","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002240","url":null,"abstract":"<p><strong>Background: </strong>The shift toward oral targeted therapies and immune checkpoint inhibitors (ICIs) in oncology has introduced pharmacokinetic variability driven by food-drug interactions (FDIs), which can cause therapeutic failure or increased toxicity.</p><p><strong>Areas of uncertainty: </strong>FDI effects depend on drug composition and food-intake timing. Evidence for traditional antineoplastic drugs is well documented, but data on newer targeted therapies and on diet-mediated or microbiome-mediated modulation of ICI efficacy remain inconsistent-dietary fiber and probiotic supplementation, for example, appear associated with divergent clinical outcomes. The role of high-dose antioxidant supplementation during cytotoxic therapy also requires further study.</p><p><strong>Data sources: </strong>A structured search of Web of Science, PubMed, and Embase (through July 2026) informed this narrative review of pharmacokinetic mechanisms, clinical outcomes, and management strategies for the concomitant use of food, dietary supplements, and antineoplastic drugs.</p><p><strong>Results: </strong>Food can alter oral antineoplastic drug bioavailability through changes in gastric pH, cytochrome P450 (CYP) modulation, and efflux-transporter inhibition (eg, P-glycoprotein). High-fat meals increase exposure to tyrosine kinase inhibitors (TKIs) such as lapatinib and abiraterone, while newer agents (sotorasib and lorlatinib) show different food-interaction profiles. ICI efficacy correlates with gut microbiome composition, modulated by dietary fiber and short-chain fatty acid production. High-dose antioxidant supplementation during cytotoxic therapy may compromise treatment outcomes.</p><p><strong>Conclusion: </strong>Food-drug interactions are an increasingly important clinical concern in modern oncology. Pharmacokinetic interactions mediated by gastric pH, CYP3A4, and P-glycoprotein transport are well supported by clinical data and already inform drug labeling, whereas diet-microbiome-immunotherapy associations remain less mature and should be regarded as hypothesis generating. Structured, multidisciplinary management-periodic regimen review, patient education, decision algorithms, and therapeutic drug monitoring-can mitigate established risks, while prospective studies are still needed before diet-based and microbiome-based interventions can be considered clinically actionable.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Janus Kinase Inhibitors for Treatment of Morphea: Report of Two Cases and a Literature Review.","authors":"Biling Jiang, Juan Bai, Qingmiao Sun, Jianjun Qiao","doi":"10.1097/MJT.0000000000002249","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002249","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Study on the Efficacy of Upadacitinib and Tofacitinib for Lichen Amyloidosis.","authors":"Yu-Ting Gan, Feng-Lin Chen, Xun Zhou","doi":"10.1097/MJT.0000000000002246","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002246","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab-Associated Reversible Lymphoid Reaction Mimicking Mycosis Fungoides.","authors":"Zeynep Utlu, Handan Bilen, Alperen Altay, Zeynep Karaca Ural, Merve Hatun Erkayman, Muhammet İspir","doi":"10.1097/MJT.0000000000002222","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002222","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}